DGAP-News

Epigenomics AG: Epigenomics AG Reports Results for the Financial Year Ended December 31, 2014 and Provides Outlook for 2015

DGAP-News: Epigenomics AG / Key word(s): Final Results
Epigenomics AG: Epigenomics AG Reports Results for the Financial Year
Ended December 31, 2014 and Provides Outlook for 2015

25.03.2015 / 07:30

---------------------------------------------------------------------

Press release

Epigenomics AG Reports Results for the Financial Year Ended December 31,
2014 and Provides Outlook for 2015

- Epi proColon(R) approved for commercialization in China

- US Approval: ADMIT trial fully enrolled; expected to report data in Q2
2015

- Strong commitment from partners; EUR 4.2 million equity investment by
BioChain

- Solid year-end financial position; liquidity at year end 2014 EUR 7.5
million

Berlin (Germany) and Germantown, MD (U.S.A.), March 25, 2015 - Epigenomics
AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American
cancer molecular diagnostics company, today announced financial results for
the fiscal year ending December 31, 2014 and provided an outlook for the
year 2015.

Dr. Thomas Taapken, CEO/CFO of Epigenomics, commented "Despite the
unexpected delay in the U.S. regulatory process for Epi proColon(R), 2014
was a successful year for Epigenomics. We obtained market approval for our
innovative and convenient blood-based colorectal cancer screening assay in
China, which represents a major milestone in the history of our Company.
Together with our partner BioChain, we are now seeking to address this
tremendous market opportunity. Approval in the U.S.A., the largest global
market for diagnostic products, is now reliant on our ADMIT trial which is
nearing completion. Together with our partners in China and the U.S.A., we
will work with healthcare organizations, key opinion leaders, payors and
patients to increase awareness and compliance to CRC screening and thus
pave the way for our commercial success."

2014 Financial Results

- In 2014, Epigenomics' total revenue amounted to EUR 1.5 million (2013:
EUR 1.6 million). The slight decrease compared to the previous year was
mainly due to the phase out of some existing licensing agreements ahead
of the expected approval of the Epi proColon(R) test kit for
commercialization in the U.S.A. Product sales fully met Epigenomics'
expectations and increased to EUR 0.8 million in 2014 from EUR 0.6
million in 2013.

- Total operating costs increased to EUR 10.4 million (2013: EUR 9.5